Cargando…
Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant tre...
Autores principales: | De Simone, Clara, Perino, Francesca, Caldarola, Giacomo, D’Agostino, Magda, Peris, Ketty |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536537/ https://www.ncbi.nlm.nih.gov/pubmed/27683143 http://dx.doi.org/10.1177/0300060515593250 |
Ejemplares similares
-
Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016) -
Suicide risk and psychiatric comorbidity in patients with psoriasis
por: Pompili, Maurizio, et al.
Publicado: (2016) -
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
por: Giunta, Alessandro, et al.
Publicado: (2016) -
Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
por: Potenza, Concetta, et al.
Publicado: (2016) -
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)